Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study

被引：0

作者：

Lee, Jung-Yun ^{[1
]}

Makker, Vicky ^{[2
,3
]}

Manso, Luis ^{[4
]}

Gonzalez-Martin, Antonio ^{[5
,6
]}

Lugowska, Iwona ^{[7
,8
,9
]}

Lorusso, Domenica ^{[10
,11
]}

Banerjee, Susana ^{[12
,13
]}

Liao, John ^{[14
]}

Lu, Chien-Hsing ^{[15
]}

Prasongsook, Naiyarat ^{[16
]}

Melichar, Bohuslav ^{[17
]}

Chen, Kai ^{[18
]}

Mcewen, Robert ^{[19
]}

Michelini, Flavia ^{[20
]}

Puvvada, Soham ^{[19
]}

Meric-Bernstam, Funda ^{[21
]}

Oaknin, Ana ^{[22
]}

机构：

[1] Yonsei Univ, Coll Med, Obstet & Gynecol, Seoul, South Korea

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[3] Weill Cornell Med Coll, Dept Med, New York, NY USA

[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] Clin Univ Navarra, Canc Ctr, Med Oncol Dept, Madrid, Spain

[6] Programme Solid Tumours Cima, Madrid, Spain

[7] Maria Sklodowska Curie Natl Res Inst, Warsaw, Poland

[8] Oncol Ctr, Early Phase Clin Trials Unit, Warsaw, Poland

[9] Dept Soft Tissue bone Sarcoma & Melanoma, Warsaw, Poland

[10] Fdn Policlin Gemelli, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Div Gynecol Oncol, Rome, Italy

[12] Royal Marsden NHS Fdn Trust, London, England

[13] Inst Canc Res, Gynaecol Unit, London, England

[14] Univ Washington, Div Gynecol Oncol, Seattle, WA USA

[15] Taichung Vet Gen Hosp, Dept Obstet & Gynecol, Taichung, Taiwan

[16] Phramongkutklao Hosp, Med Oncol Unit, Bangkok, Thailand

[17] Palacky Univ, Univ Hosp, Med Sch, Dept Oncol, Olomouc, Czech Republic

[18] AstraZeneca, Oncol Randd, Gaithersburg, MD USA

[19] AstraZeneca, Oncol Randd, Cambridge, England

[20] AstraZeneca, Translat Med, Oncol Randd, Waltham, MA USA

[21] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

[22] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO007LBA

引用

页码：A6 / A7

页数：2

共 50 条

[1] Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana
Gonzalez-Martin, Antonio
Jung, Kyung Hae
Lugowska, Iwona
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Fielding, Anitra
Ma, Yan
Puvvada, Soham
Shire, Norah
Lee, Jung-Yun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) : 47 - +
[2] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana N.
Martin, Antonio Gonzalez
Jung, Kyung Hae
Lugowska, Iwona A.
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Anoka, Chiedozie
Ma, Yan
Puvvada, Soham D.
Lee, Jung-Yun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA3000 - LBA3000
[3] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
Wysocki, Piotr Jan
Jung, Kyung Hae
Oh, Do-Youn
Doroshow, Deborah Blythe
Artamonova, Elena
Mammatas, Lemonitsa
Su, Po-Jung
Moiseyenko, Vladimir
Penkov, Konstantin
Stroyakovskiy, Daniil
Bartolome, Jorge
Siena, Salvatore
Fielding, Anitra
Jung, Lindsey
Michelini, Flavia
Puvvada, Soham D.
Makker, Vicky
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Oaknin, Ana
Lee, Jung-Yun
Makker, Vicky
Oh, Do-Youn
Banerjee, Susana
Gonzalez-Martin, Antonio
Jung, Kyung Hae
Lugowska, Iwona
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Fielding, Anitra
Puvvada, Soham
Smith, Ann
Meric-Bernstam, Funda
[J]. ADVANCES IN THERAPY, 2024,
[5] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Meric-Bernstam, F.
Makker, V.
Oaknin, A.
Oh, D. Y.
Banerjee, S.
Martin, A. Gonzalez
Jung, K. H.
Lugowska, I.
Manso, L. M.
Manzano, A.
Melichar, B.
Siena, S.
Stroyakovskiy, D.
Fielding, A.
Ma, Y.
Puvvada, S. D.
Lee, J. Y.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1274
[6] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Oh, D-Y.
Meric-Bernstam, F.
Makker, V.
Oaknin, A.
Banerjee, S.
Gonzalez Martin, A.
Jung, K. H.
Lugowska, I.
Manso, L. M.
Manzano, A.
Melichar, B.
Siena, S.
Stroyakovskiy, D.
Fielding, A.
Ma, Y.
Puvvada, S. D.
Lee, J-Y.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S1494 - S1495
[7] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
Meric-Bernstam, Funda
Kim, Seung Tae
Parinyanitikul, Napa
Moreno, Alberto
Lin, Chia-Chi
Gornastolev, Dmitry
Chindaprasirt, Jarin
Lugowska, Iwona A.
Stroyakovskiy, Daniil
Jassem, Jacek
Harrison, Michelle L.
Ostwal, Vikas S.
Michelini, Flavia
Jung, Lindsey
Kuptsova-Clarkson, Nataliya
Puvvada, Soham D.
Gan, Hui Kong
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana N.
Martin, Antonio Gonzalez
Jung, Kyung Hae
Lugowska, Iwona A.
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Anoka, Chiedozie
Ma, Yan
Puvvada, Soham D.
Lee, Jung-Yun
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[9] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
Meric-Bernstam, F.
Anoka, C.
Dobrowolska, A.
Chaudhry, A.
Rowbottom, J.
Gustavson, M.
Puvvada, S.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254
[10] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Makker, V.
Lee, J-Y.
Oh, D-Y.
Oaknin, A.
Puvvada, S. D.
Cecchi, F.
Mcewen, R.
Michelini, F.
Meric-Bernstam, F.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240

← 1 2 3 4 5 →